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MEK1/2 inhibitors such as AZD6244 are in clinical trials for the treatment of multiple cancers, including breast cancer. Targeted
kinase inhibition can induce compensatory kinome changes, rendering single therapeutic agents ineffective. To identify target
proteins to be used in a combinatorial approach to inhibit tumor cell growth, we used a novel strategy that identified microRNAs
(miRNAs) that synergized with AZD6244 to inhibit the viability of the claudin-low breast cancer cell line MDA-MB-231. Screen-
ing of a miRNA mimic library revealed the ability of miR-9-3p to significantly enhance AZD6244-induced extracellular signal-
regulated kinase inhibition and growth arrest, while miR-9-3p had little effect on growth alone. Promoter methylation of mir-9
genes correlated with low expression of miR-9-3p in different breast cancer cell lines. Consistent with miR-9-3p having synthetic
enhancer tumor suppressor characteristics, miR-9-3p expression in combination with MEK inhibitor caused a sustained loss of
c-MYC expression and growth inhibition. The 1 integrin gene (ITGB1) was identified as a new miR-9-3p target, and the growth
inhibition seen with small interfering RNA knockdown or antibody blocking of ITGB1 in combination with MEK inhibitor phe-
nocopied the growth inhibition seen with miR-9-3p plus AZD6244. The miRNA screen led to identification of a druggable pro-
tein, ITGB1, whose functional inhibition synergizes with MEK inhibitor.
The continued interest in kinases as cancer therapeutic targets isdemonstrated by the more than 130 kinase-directed inhibitors
currently in clinical trials. Despite inhibitor-specific targeting of
dysregulated kinases in different cancers, this approach has
yielded only limited success due to the development of therapeutic
resistance. In addition to somatic mutation and modulation of
kinase expression, cancer cells readily exploit alternate kinase net-
works to bypass targeted kinase inhibition (1, 2). Receptor ty-
rosine kinase (RTK) upregulation and activation is one mecha-
nism of acquired resistance. In melanoma, BRAF inhibition drives
upregulation of the RTKs platelet-derived growth factor receptor
 (PDGFR) and insulin-like growth factor 1 receptor (IGF1R)
(3), while in glioblastoma, the activation of MET and PDGFR
can circumvent epidermal growth factor receptor inhibition (4).
Understanding inhibitor-driven reprogramming of kinase net-
works will be required to effectively design combination kinase
inhibitor therapies to target cancer subtypes.
The claudin-low breast cancer subtype represents 20 to 30% of
triple-negative breast cancer (TNBC) cases and 10% of all breast
cancer cases and is characterized by low expression of the claudin
genes and other junctional proteins, including E-cadherin (5).
Although claudin-low tumors share basal-like features, they are
distinct in that they possess stem cell characteristics with high
expression of mesenchymal and epithelial-mesenchymal transi-
tion (EMT) genes and are thought to be reflective of the least-
differentiated stage of epithelial development (6). Claudin-low
characteristics are also common in chemotherapy-resistant breast
tumors.
Synthetic lethal screens using RNA interference (RNAi) in the
context of tumor-suppressive or oncogenic mutations have
proven to be successful in identifying previously unknown gene
interactions controlling the cancer cell phenotype (7, 8). Addi-
tionally, RNAi screens have uncovered synthetic interactions in
the context of pharmacological kinase inhibition, which has the
potential to facilitate the design of effective combination thera-
pies.
We therefore sought to identify microRNAs (miRNAs) that
synergized with pharmacological MEK1/2 inhibition in claudin-
low TNBC cells with the rationale that the claudin-low phenotype
is the most difficult to treat, with few oncoproteins for molecular
targeting with currently developed inhibitors identified. miRNAs
conferring synthetic enhancement of MEK1/2 inhibition pro-
vided identification of miRNA target genes that could be pharma-
cologically inhibited. Herein we report the ability of miR-9-3p to
attenuate cell proliferation in the presence of MEK inhibition. We
identify the 1 integrin gene (ITGB1) to be a novel target of miR-
9-3p and demonstrate that loss of c-MYC expression contributes
to the synthetic enhancement seen with this miRNA in combina-
tion with MEK1/2 inhibitor.
MATERIALS AND METHODS
Cell culture. MDA-MB-231 cells were maintained in Iscove’s modified
Dulbecco’s medium (Life Technologies, Carlsbad, CA) with 10% fetal
bovine serum (FBS) and an antibacterial-antimycotic cocktail (Gemini
Bio-Products, West Sacramento, CA). SUM159PT cells were maintained
in F-12 medium (Life Technologies) with 5% FBS, 5 g/ml insulin, 1
g/ml hydrocortisone, and an antibacterial-antimycotic cocktail.
Drugs. AZD6244 (selumetinib) was obtained from LC Laboratories
(Woburn, MA), and GSK1120212 (trametinib) was obtained from Selleck
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Chemicals (Houston, TX). Drugs were added to cells during plating and
not replenished.
Reverse transfection. For all studies, 25 nM (final concentration)
small interfering RNA (siRNA; SMARTpool or individual) or miRNA
mimic (Thermo Fisher Scientific Dharmacon, Lafayette, CO) was com-
plexed with the DharmaFECT 1 reagent (1.0 l/ml for MDA-MB-231
cells and 0.75 l/ml for SUM159PT cells; Thermo Fisher Scientific Dhar-
macon) for 30 min, followed by addition of cells in complete medium.
Dharmacon miRIDIAN mimic negative control 1 (CN-001000-01-05)
and siGENOME control pool nontargeting 2 (D-001206-14-05) were
used as controls. The following individual MYC siRNAs were used: (i)
Dharmacon D-003282-16, (ii) D-003282-14, and (iii) D-003282-35.
Primary screen. Beckman Coulter (Indianapolis, IN) Biomek FXP
automation was used to dispense miRNA mimic representing a Dharma-
con miRIDIAN human mimic microRNA library (CS-001010; lot 10100;
miRBase, release 13) into 384-well (Clear; Greiner Bio-One, Monroe,
NC) daughter plates in triplicate. Columns 1, 23, and 24 of the 384-well
plates did not contain miRNA for baseline controls. A MicroFlo Select
instrument (BioTek Instruments, Winooski, VT) was used to dispense
medium to form miRNA/DharmaFECT 1 complexes in a 10-l volume
per well. Complexes formed for 30 min, followed by addition of a 40-l/
well MDA-MB-231 cell suspension containing AZD6244 or dimethyl sul-
foxide (DMSO) vehicle control, resulting in a final volume of 50 l per
well and 1.5 M AZD6244. Cells were incubated for 96 h, followed by the
addition of 7 l CellTiter-Glo reagent (Promega, Madison, WI) per well.
Luminescence was assessed using a PHERAstar FS plate reader (BMG
Labtech, Cary, NC).
Data analysis. Row median values were determined by dividing the
raw luminescence value of the well by the median luminescence value of
the corresponding row from columns 3 to 22. The mean row median value
of the three replicate wells was then calculated, followed by determination
of the ratio of the mean row median value for DMSO treatment to the
mean row median value for AZD6244 treatment. Wells with DMSO/
AZD6244 mean row median values of 1 were defined as synthetic en-
hancer wells; values of 1 indicated synthetic recovery.
Quantitative RT-PCR. RNA was purified from all cell lines using a
Qiagen (Valencia, CA) miRNeasy kit. Fifty nanograms of RNA was used
for reverse transcription (RT) using TaqMan microRNA assay (Applied
Biosystems, Foster City, CA) primers specific for hsa-miR-9-3p (hereafter
called miR-9-3p) or U6 snRNA. A total of 1.33 l of each 15-l RT reac-
tion mixture was used for quantitative PCRs using a 7500 real-time RT-
PCR system (Applied Biosystems).
DNA methylation assays. For methyltransferase inhibitor experi-
ments, cells were treated with 5 M 5-aza-2=-deoxycytidine (5AZA;
Sigma, St. Louis, MO) or DMSO vehicle control for 48 h. For combined
bisulfite restriction analysis (COBRA), genomic DNA was isolated using a
Qiagen DNeasy blood and tissue kit and bisulfite treated using an EZ DNA
methylation gold kit (Zymo Research, Irvine, CA). The following primers
were used for CpG island PCR amplification of bisulfite-treated DNA, as
originally described in reference 9: for the mir-9-1 248-bp amplicon, GA
TTTAGGTAGAGGTTTTTTTAGTTT and TTAACTACCCATTTCCCC
TTTTAAT; for the mir-9-2 181-bp amplicon, ATGTTAGGAAAATAAA
GTTGGGGTT and CCCCTCCTCTAAAACAACTAAAAA; and for the
mir-9-3 220-bp amplicon, GTTTGTTTATTTTTTTTGGTTTTT and AA
ATTATAAAAATCATTTCTACTTTC.
Amplicons were digested with BstUI (mir-9-1 and mir-9-3) or TaqI
(mir-9-2) (New England BioLabs, Ipswich, MA) and run on 2% agarose
gels with undigested product.
ChIP-PCR. SUM149 or MDA-MB-231 cells were fixed for 10 min in
1% formaldehyde, sonicated (VCX130 ultrasonicator; Sonics, Newtown,
CT), and immunoprecipitated with 5 g H3K9me3 (Abcam 8898) or
H3K27me3 (6002; Abcam) antibody and protein A Dynabeads (Life
Technologies). Cross-linking was reversed by incubation at 65°C over-
night, and DNA was purified using a MinElute PCR purification kit (Qia-
gen). The following primer pairs, designed to yield 100-bp amplicons
within 500 bp of the 5= sequence flanking each hairpin, were used for ChIP
real-time PCR: for mir-9-1, GTCCTTTCCACGCCTTTTTC and CGTCA
GCGGGAGTAGGAG; for mir-9-2, TAACGCTGCCGGAGATTACT and
TACTTGCCGCGCTTAAGATT; for mir-9-3, CATTGTAAGGCTGGGT
GGTG and CCTCCTCTCGCAGGCTAATC; and for EEF1A1, CGTCAT
CACTGAGGTGGAGA and GGAGCCAGTACACGACATCA.
Chromatin immunoprecipitation (ChIP)–real-time PCR was per-
formed using Absolute Blue SYBR green PCR mix (Thermo Fisher Scien-
tific, Waltham, MA) and a Fast 7500 real-time PCR system (Applied Bio-
systems). Fold enrichment was calculated by the 2CT method.
Flow cytometry. SUM159PT cells were reversed transfected with ei-
ther control miRNA mimic/miR-9-3p mimic or control siRNA/ITGB1
siRNA and concurrently treated with 250 nM AZD6244 for 96 h. For each
condition, 5.0 	 105 cells were rinsed once with phosphate-buffered sa-
line (PBS), centrifuged at 1,000 rpm for 5 min, and resuspended in 0.5 ml
PBS. The cell suspension was then added to 4.5 ml 70% ethanol and
incubated at 20°C overnight. The cells were then centrifuged at 1,000
rpm for 5 min, rinsed once with PBS, and then incubated in 1 ml pro-
pidium iodide staining solution (0.1% Triton X-100, 200 g/ml RNase A
[Sigma], 20 g/ml propidium iodide [Sigma]) at room temperature for 30
min. Stained cells were kept at 4°C until analyzed in a Beckman Coulter
CyAn ADP flow cytometer. Cell cycle stage quantification from 1.0 	 104
analyzed cells and plots were generated using ModFitLT v3.2.1 software
(Verity Software House).
Time-lapse imaging. MDA-MB-231 or SUM159PT cells were reverse
transfected in 35-mm glass-bottom culture dishes (MatTek Corporation,
Ashland, MA) or treated with 2.5 g/ml monoclonal antibody AIIB2 (De-
velopmental Studies Hybridoma Bank, University of Iowa) or normal rat
IgG lacking azide (Santa Cruz Biotechnology, Santa Cruz, CA). Cells were
treated with 500 nM (MDA-MB-231) or 250 nM (SUM159PT) AZD6244
or DMSO vehicle control. Differential interference contrast (DIC) imag-
ing was started at 24 h posttransfection in an Olympus VivaView FL
LCV110 CO2 incubator microscope, using 	20 magnification and 1-by-1
binning with 10- or 20-min intervals for 30 to 60 h. Images were assem-
bled into stacks and contrast adjusted using ImageJ v1.45s software.
Immunoblots and antibodies. Cells were lysed in 20 mM Tris-HCl
(pH 8.0), 1% NP-40, 10% glycerol, 137 mM NaCl, 2 mM EDTA, protease
inhibitor cocktail tablet (Roche, Basal, Switzerland), and 1% phosphatase
inhibitor cocktails 1 and 3 (Sigma) and cleared by centrifugation. The
following antibodies were used: extracellular signal-regulated kinase 2
(ERK2) C14 (Santa Cruz Biotechnology), BIM 17003 (EMD Millipore
Chemicon, Billerica, MA), and phospho-ERK1/2 4370, ITGB1 4706, c-
MYC 5605, PDGFRB 3169, and DDR1 5583 (Cell Signaling Technology,
Danvers, MA).
Migration and invasion assays. Cells were reverse transfected and
grown for 48 h posttransfection in the presence of 500 nM (MDA-MB-231
cells) or 250 nM (SUM159PT cells) AZD6244. For migration assays, 5.0 	
104 MDA-MB-231 or 4.0 	 104 SUM159PT cells were plated in Tran-
swells with an 8-m pore size (Costar 3422; Corning) and drug- or
DMSO-containing medium in both chambers. After 24 h, cells were fixed
and stained with DAPI (4=,6-diamidino-2-phenylindole). Five fields per
membrane were imaged at 	10 magnification, followed by intensity
masking and counting of nuclei using SlideBook software (Intelligent Im-
aging Innovations, Inc., Denver, CO). Invasion assays were performed as
described above using 8-m-pore-size Matrigel Transwells (354483; BD
Biosciences) and 5.0 	 104 MDA-MB-231 or SUM159PT cells per Trans-
well. For assays using blocking antibody, cells were pretreated with 2.5
g/ml AIIB2 or control rat IgG for 48 h in the presence of DMSO or
AZD6244 at the concentrations listed above. Cells (4.0 	 104) were then
seeded in Transwells containing 2.5 g/ml AIIB2, and the assays were
performed as described above.
3= UTR/miRNA luciferase reporter assays. Firefly/Renilla reporter
plasmid pEZX-MT01 harboring the human ITGB1 3= untranslated region
(UTR; clone HmiT009810-MT01) and Luc-Pair miR luciferase assay re-
agents were obtained from GeneCopoeia (Rockville, MD). Five thousand
miR-9-3p and MEK Inhibitor Synergy
June 2013 Volume 33 Number 11 mcb.asm.org 2261
FIG 1 miR-9-3p is a synthetic enhancer of MEK inhibition in MDA-MB-231 cells. (A) Heat maps (MARS software; BMG LabTech) depicting the reproducibility
between triplicate microplates of the primary screen for one daughter plate of a Dharmacon human miRIDIAN microRNA mimic library. Color bar scales for
replicate DMSO- and AZD6244-treated plates represent raw luminescence counts from the CellTiter-Glo (Promega) growth inhibition/viability assay, depen-
dent on cellular ATP concentration. (B) Scatter plot showing the distribution of primary synthetic enhancer screen. DMSO/AZD6244 row median ratios of 1.0
indicate synthetic enhancement, while ratios of 1.0 represent synthetic recovery. The five highest-ranking synthetic enhancer miRNA mimics are indicated, and
the screen position of miR-9-5p (arrow) is shown to contrast its opposing effect on cell proliferation compared to that of its counterpart strand, miR-9-3p. (C)
Distribution of the primary screen plotted as a spectrum of decreasing synthetic enhancement to increasing synthetic growth rescue. The rankings of miR-9-3p
and miR-9-5p are indicated by arrows. (D) CellTiter-Glo assay from the primary screen showing miR-9-3p/AZD6244 synthetic enhancement and the opposite
growth phenotypes of miR-9-3p and miR-9-5p mimics. Error bars represent SEMs of triplicate microplate wells. (E) Immunoblot showing the miR-9-3p-
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MDA-MB-231 cells were transfected with 100 ng plasmid and 100 nM
miRNA mimic per well in 96-well Clear plates using 0.4 l Dharma-
FECT Duo reagent (Thermo Fisher Scientific Dharmacon). For creation
of the mutant pEZX-MTO1 construct, the ITGB1 3= UTR insert from the
wild-type construct was synthesized (Genewiz, South Plainfield, NJ) with
mutations at three putative miR-9-3p binding sites and cloned into
pEZX-MT01 as an EcoRI/XhoI fragment. The miR-9-3p binding site mu-
tations were created by changing the ITGB1 3= UTR sequence at miRNA
seed positions m2, m3, and m8 from AGCUUUA (wild type) to CGC
UUCC (mutant). Luminescence was assessed at 48 h posttransfection.
RESULTS
miR-9-3p is a sensitizer of MEK inhibitor-induced growth ar-
rest. To identify miRNAs that reduced cell proliferation/viability
in the presence of MEK inhibition, we screened miRNA mimics
representing 878 human miRNAs. MDA-MB-231 claudin-low
breast cancer cells were used in the primary screen because of their
sensitivity to MEK inhibitor-induced growth arrest (10, 11). The
highly specific, allosteric MEK inhibitor AZD6244 (12), currently
in clinical trials for the treatment of several cancers, including
breast cancer, was utilized for MEK inhibition. A dose of 1.5 M
AZD6244 reduced MDA-MB-231 cell proliferation/viability by
25%, allowing a dynamic range sufficient to detect synthetic
enhancer interactions upon miRNA mimic transfection. A row
median metric comparing the value for each well to the median
luminescence value for the given microplate row was then used to
score cell viability following the CellTiter-Glo (Promega) lumi-
nescence-based assay dependent on the cellular ATP concentra-
tion. Heat maps depict the reproducibility of the assay across trip-
licate microplates (Fig. 1A).
We ranked the miRNA mimics in terms of their degree of syn-
thetic enhancement with MEK inhibition by comparing the row
median score between the DMSO vehicle-treated condition and
the AZD6244-treated condition. Wells with the highest DMSO/
AZD6244 row median luminescence ratios represented synthetic
enhancer hits (see Table 1 for the top 10 hits). Figures 1B and C
show the distribution of miRNAs according to synthetic enhance-
ment (see Dataset S1 in the supplemental material for complete
screen rankings and raw data). We initially utilized bioinformatics
algorithms to predict candidate target mRNAs for the top five
synthetic enhancer miRNA hits (miR-205-3p, miR-9-3p, miR-
548k, miR-432-3p, miR-613). Our criteria involved (i) prediction
of target miRNAs by two different algorithms among the Micro-
Cosm Targets (13), microRNA.org (14), PicTar (15), and Target-
Scan (16) algorithms and (ii) the need for target mRNA to encode
a protein that could be inhibited pharmacologically with available
small molecules or biologicals and to rank within the top 20 tar-
gets predicted by each algorithm. The rationale for these criteria
was the ability to rapidly screen inhibitors to mimic the pheno-
types observed with the miRNA in combination with MEK inhib-
itor. There was a lack of obvious druggable target molecules pre-
dicted for miR-205-3p, miR-548k, miR-432-3p, and miR-613
(Table 2). We therefore focused efforts on miR-9-3p (miR-9*), as
it was predicted to target 1 integrin (ITGB1), a protein for which
function-blocking antibodies are available and that is well estab-
lished to be important for growth factor receptor and extracellular
matrix-regulated signaling (17).
Transfection of miR-9-3p in the absence of drug had a minimal
effect on cell proliferation/viability, reducing the mean raw lumi-
nescence counts to 87.4% of the count for control cells lacking
miRNA. In the presence of AZD6224, synthetic enhancement was
observed, with raw counts being reduced to 37.9% of that for the
control (Fig. 1D). In contrast, miR-9-5p, the 5= (non-star form)
counterpart to miR-9-3p, had a reciprocal ranking in the primary
screen, whereby miR-9-5p transfection resulted in a synthetic res-
cue causing an increase in growth with MEK inhibition (Fig. 1D).
Concordant with these opposing effects of miR-9-3p and miR-
9-5p on cell growth in the presence of MEK inhibition, immuno-
blotting revealed the ability of miR-9-3p to further decrease
phospho-ERK1/2 levels in response to AZD6244 treatment, while
miR-9-5p resulted in increased phospho-ERK1/2 levels (Fig. 1E).
miR-9-3p and MEK inhibition regulate c-MYC expression.
There is evidence that mir-9 transcription is regulated by c-MYC
(18), and conversely, miR-9-3p overexpression has been shown to
decrease c-MYC protein expression (19), suggesting a complex
feedback regulation. In addition, ERK1/2 phosphorylates c-MYC
at serine 62 and stabilizes the protein from proteasomal degrada-
tion (20). We have previously shown in claudin-low cells that
MEK inhibition results in rapid c-MYC degradation via ERK, with
RTK upregulation ultimately leading to resistance to MEK inhib-
itors (10). Treatment for 48 h with 10 nM GSK1120212, a MEK1/2
inhibitor that has increased potency relative to AZD6244 but that
targets the same allosteric regulatory site in MEK1 and MEK2
(21), resulted in c-MYC loss, concordant with the findings of our
previous kinome reprogramming study (Fig. 1F). We have previ-
ously shown for both MDA-MB-231 cells and a second claudin-
low breast cancer cell line, SUM159PT, that the c-MYC protein is
initially degraded in response to low-dose MEK inhibitor but re-
turns to near control levels over time as the cells reprogram their
mediated reduction or miR-9-5p-mediated increase of phospho-ERK1/2 in the presence of 1.5 M AZD6244 in MDA-MB-231 cells. (F) MDA-MB-231 or
SUM159PT immunoblots showing a loss of c-MYC upon 48 h of 10 nM GSK1120212 treatment. (G) Immunoblots showing a sustained loss of c-MYC upon 96
h of miR-9-3p and AZD6244 dual treatment in MDA-MB-231 or SUM159PT cells. MDA-MB-231 cells were treated with 500 nM AZD6244, and SUM159PT cells
were treated with 250 nM AZD6244. (H) MDA-MB-231 hemocytometer cell counts following transfection with control siRNA or three individual c-MYC
siRNAs in the presence or absence of 500 nM AZD6244. Error bars represent SEMs of three experiments. *, P  0.05 between control siRNA in the presence of
AZD6244 and each individual MYC siRNA in the presence of AZD6244. Loading controls for all immunoblots were ERK2 and actin.
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kinome and overcome MEK inhibition (10). Thus, even though
c-MYC is rapidly degraded with MEK inhibition, c-MYC levels
return to control levels after 96 h (Fig. 1G). Expression of miR-
9-3p synergized with MEK inhibitor to sustain a loss of c-MYC
protein after 96 h, whereas miR-9-3p mimic or MEK inhibition
alone led to a level of recovery of c-MYC expression similar to
control levels (Fig. 1G). In both MDA-MB-231 and SUM159PT
cells, loss of c-MYC expression leads to an upregulation of multi-
ple receptor tyrosine kinases within 24 h of MEK inhibition (10).
We observed kinome reprogramming characterized by AZD6224-
induced upregulation of PDGFR and DDR1 receptor tyrosine
kinase in SUM159PT cells expressing miR-9-3p (not shown), in-
dicating that miR-9-3p does not influence kinome reprogram-
ming while sustaining suppression of c-MYC expression. RNAi
knockdown of c-MYC expression resulted in cell growth inhibi-
tion, which was further potentiated by AZD6244 treatment (Fig.
1H). Cumulatively, these results show that the suppression of c-
MYC expression with the combination of MEK inhibitor and
miR-9-3p expression inhibits growth of MDA-MB-231 cells.
Epigenetic silencing of miR-9 loci. Initial quantitative RT-
PCR studies using probes for mature miR-9-3p revealed high cycle
threshold (CT) values in both MDA-MB-231 (CT 
 30.4) and
SUM159PT (CT 
 35.8) cells (Fig. 2A). The expression of miR-
9-3p in additional claudin-low cell lines, WHIM12 and BT549,
yielded comparable CT values of 30.2 and 31.3, respectively. We
screened additional breast cancer cell lines, including Her2/Neu
amplified, basal, and luminal subtypes. The cell line with the high-
est relative miR-9-3p expression was SUM149 basal-like cells,
with a CT value of 26.9, representing a 600-fold relative quanti-
fication (RQ) value relative to the levels of miR-9-3p in
SUM159PT cells. We found that, with the exception of SUM149
cells, overall miR-9-3p expression was low or nearly nondetect-
able in the tested breast cancer lines, including telomerase-im-
mortalized human mammary epithelial cells.
There are three miR-9 genes, mir-9-1, mir-9-2, and mir-9-3,
transcribed from different chromosomal loci (Fig. 2B), yet all
yield identical mature miRNA products. Following a bioinfor-
matic search for candidate CpG islands 5= of miRNA genes, it was
initially shown that the mir-9-1 gene was hypermethylated in pri-
mary invasive breast tumors (22). Additional studies have since
shown that mir-9 loci are epigenetically silenced in gastric tumors
(9), breast mammosphere models (23), oral squamous cell carci-
noma (24), and non-small-cell lung cancers, where methylation of
mir-9-3 can serve as a prognostic indicator (25, 26). To see if
methylation was a contributing silencing mechanism in our sys-
tem, we first treated cells with the methyltransferase inhibitor
5-aza-2=-deoxycytidine (5AZA). Following 48 h of 5 M 5AZA
treatment in SUM159PT cells, quantitative RT-PCR showed a
14.8-fold increase in the levels of miR-9-3p relative to those in
vehicle-treated control cells, while the levels of an oncogenic
miRNA transcript not expected to be silenced, miR-21, did not
change (Fig. 2C). These data suggested that promoter methylation
contributed to the low level of miR-9-3p in claudin-low cells. To
validate this suggestion, we performed COBRA (9, 27) (Fig. 2D).
In the claudin-low lines tested, prominent CpG island methyl-
ation was detected at all three mir-9 genes for MDA-MB-231 cells,
at mir-9-1 and mir-9-2 in SUM159PT cells, and at mir-9-2 in
WHIM12 cells. For all but one cell line assayed (SUM149), differ-
ent claudin-low, Her2/Neu-overexpressing, and luminal subtype
cell lines tested had methylation of at least one mir-9 locus, but,
more commonly, multiple mir-9 loci were methylated. The
SUM149 cell line was not methylated at any of the three loci and
concordantly showed the highest levels of endogenous miR-9-3p
expression.
As epigenetic mechanisms in addition to cytosine methylation
could be contributing to mir-9 silencing, we profiled histone H3
trimethylation at the three mir-9 genomic loci by chromatin im-
munoprecipitation-PCR. Consistent with transcriptional repres-
sion of miR-9-3p in MDA-MB-231 cells but not in SUM149 cells
(Fig. 2A), a 4.5-fold enrichment of lysine 9 trimethylation of his-
tone H3 (H3K9) in MDA-MB-231 cells relative to SUM149 cells
was detected within the 500 bp 5= of the mir-9-1 hairpin but not
appreciably at the mir-9-2 or mir-9-3 locus (Fig. 2E). We failed to
detect significant trimethylation of histone H3K27 in MDA-MB-
231 cells relative to SUM149 cells at any of the three mir-9 loci.
Analysis of The Cancer Genome Atlas (TCGA) breast cancer da-





miR-9-3p miR-205-3p miR-548k miR-432-3p miR-613
MicroCosm microRNA.org PicTar microRNA.org TargetScan microRNA.org MicroCosm microRNA.org MicroCosm microRNA.org
1 TCEA1P2 TSNAX PNUTL2 CEP350 MAP9 FNDC3B FAM169B GSG1L NR1H3 TMTC3
2 DPYSL3 PPM1A CDK11 CSGALNACT2 LIN7C BRD1 GSG1L FAM169B WDR61 SUSD1
3 CETN3 ZNF292 CLK3 C11orf73 GULP1 SKIL TLK2 TMCO4 NP_612412.2 GJA1
4 LRRTM1 LOC641367 CDH11 RBMS1 FNDC3B ARID4B TM9SF3 LAMC2 SH3BGRL3 YLPM1
5 RNASE6 CCNYL1 RAB11FIP1 DMRT1 KITLG ZNF611 LYST TXNDC2 STRAD_HUMAN SLC44A1
6 NFATC3 HIAT1 PHB TMEM188 BRD1 MYST3 PRKCA HOXD10 SOX30 BDNF
7 MTBP ITGB1 FLJ32096 EXOC8 SUV420H1 RIMS1 ATL2 MEIS3 TRAPPC4 PTPLAD1
8 NP_056996.2 GABRA1 CHN1 TOPBP1 CD47 WNT5A YPEL2 FTSJD1 KCTD13 GLCCI1
9 CGA LIMA1 NFAT5 GJA1 TANC1 LIN7C CDH6 RIF1 PGM2 UTRN
10 KIAA0133 MPPED2 MGRN1 ARID4A UHMK1 UBE2B SLC8A1 PLBD2 PGD ZNF547
11 NSMCE4A COL4A3BP FLJ43374 HOXA13 TGFBR1 PAXIP1 PKP2 GPM6A ABCB7 DGUOK
12 HCC1_HUMAN ZNF664 YBX2 APC MGAT4A BCL10 ITGAV ATL2 MYEF2 MGC70870
13 EAPP C12orf36 PPARBP PHF20L1 UBE2B HIAT1 C18orf1 C1orf43 C14orf159 UST
14 MTA1 PCDHA4 LOC114990 RBMS1 ARID4B ARMC8 NELL1 PIP5K1B GAK C14orf45
15 KIAA1217 PCDHA6 MGC19764 LIN9 OTUD4 TANC1 MRPL9 XKR4 GDAP1L1 WNK3
16 CLK1 PCDHAC2 ZFHX1B CELF2 CDC2L6 ZNF493 DCLRE1B GCLM SPEG E2F5
17 ITGB1 PCDHA2 MLR2 PCDHA4 PAPD5 C1D NPAT PTENP1 IFT52 CHSY1
18 TPD52 PCDHA10 DKFZP566B183 PCDHA13 FMR1 FMR1 GPM6A SIK3 PTPRN TRAPPC3
19 KIAA0368 PCDHA7 RNF4 PCDHA5 SEMA6D CSNK1G3 CADM2 EXTL2 YRDC PAX3
20 KIAA0284 PCDHA12 ESM1 LOC645166 CDK6 FZD7 SARM1 GRIPAP1 RSBN1 TNKS2
a The predicted ITGB1 targets are in boldface.
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FIG 2 mir-9 loci are methylated in breast cancer subtype cell lines. (A) Quantitative RT-PCR analysis of mature miR-9-3p across breast cancer subtype
cell lines. CT values are indicated for each cell line, showing low relative levels of mature miR-9-3p in claudin-low lines and the highest relative expression
in the basal line SUM149. U6 snRNA was used for the quantitative RT-PCR internal control. HMEC, human mammary epithelial cells. (B) Schematic of
the three mir-9 genomic loci. CpG islands assayed for methylation (see the legend to panel D below) are depicted in red (9); proximal CpG islands are
shown in black. Arrows indicate the direction of transcription. Genomic coordinates were determined using the hg19 genome assembly (UCSC Genome
Browser). Chr., chromosome. (C) Quantitative RT-PCR analysis showing induction of mature miR-9-3p expression upon 5 M 5-aza-2=-deoxycytidine
(5AZA) treatment in SUM159PT cells. U6 snRNA was used for the quantitative RT-PCR internal control. (D) COBRA methylation assay for the three
mir-9 genes across breast cancer subtype cell lines. The CpG islands assayed for methylation are schematized in panel B as red rectangles. Arrows indicate
the size of the methylated allele upon restriction digestion of bisulfite-treated DNA. Red asterisks indicate which cell lines show predominant CpG island
methylation at each mir-9 locus. Lanes M, molecular size markers, with the molecular sizes indicated on the left. (E) ChIP-PCR showing relative H3K9me3
or H3K27me3 enrichment at the mir-9 loci in MDA-MB-231 cells normalized to SUM149 levels. A constitutively active gene, EEF1A1, was chosen as a
negative control for histone H3 lysine trimethylation. DNA methylation at the mir-9-1 locus (F) or mir-9-3 locus (G) in human breast tumors of the
indicated subtype in the TCGA database. By the Wilcoxon rank sum test, P was equal to 1.505E5 (mir-9-1) or 2.146E5 (mir-9-3) between normal
breast-like tumors and tumors of all other subtypes. Methylation status was determined using Illumina Infinium 450K arrays and quantified by calculating
the methylated probe intensity to the total intensity at each locus. Results for 332 tumors are as follows: basal 
 46, Her2 
 24, LumA 
 151, LumB 

88, and normal breast-like 
 23. Genomic coordinates (hg19) of CpG island methylation probes are indicated.
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tabase showed CpG island methylation at both the miR-9-1 and
miR-9-3 promoters in four breast cancer subtypes (Fig. 2F and G).
Claudin-low tumors as well as the miR-9-2 gene were not repre-
sented in the TCGA DNA methylation data set (28). Thus, in the
breast cancer cell lines tested (except for SUM149) and human
breast cancers, mir-9 gene promoters have significant CpG island
methylation, suggesting that DNA methylation contributes to the
epigenetic silencing of mir-9.
miR-9-3p sensitizes MDA-MB-231 and SUM159PT cells to
MEK inhibitor-induced growth arrest. miR-9-3p mediated a
synthetic growth suppression phenotype in MDA-MB-231 cells
and in SUM159PT cells in the presence of the MEK inhibitor
AZD6244 (Fig. 3A and B). A similar synthetic enhancer effect was
observed with a second MEK inhibitor also in clinical trials,
GSK1120212, demonstrating that the synthetic enhancement seen
with miR-9-3p is a function of a cooperative effect of the miRNA
and MEK inhibition. Expression of miR-9-3p had a modest but
measureable effect alone on growth of MDA-MB-231 cells but not
SUM159PT cells. This baseline effect contributed to SUM159PT
cells displaying an increased miR-9-3p/MEK inhibition synthetic
effect relative to MDA-MB-231 cells upon renormalization of the
growth curves to the DMSO value for each miRNA, control, or
miR-9-3p (Fig. 3B). miR-9-3p sensitized both cell lines to low-
dose MEK inhibitor, demonstrating that miR-9-3p is targeting
genes whose expression is required for ERK1/2-dependent cell
proliferation. Consistent with results of the primary screen, miR-
9-5p failed to yield the synthetic enhancement driven by the miR-
9-3p form and, instead, decreased the relative growth inhibition of
both cell lines in response to MEK inhibitor.
We further characterized the growth arrest caused by miR-
9-3p plus MEK inhibitor by flow cytometry. Cell cycle staging by
propidium iodide staining yielded the expected G0/G1 arrest in
SUM159PT cells following 96 h of treatment with a high dose of
MEK inhibitor (500 nM GSK1120212) that sustains MEK inhibi-
tion and a loss of c-MYC expression (10). In contrast, a modest
dose of MEK inhibitor in combination with miR-9-3p gave only
partial arrest of cell proliferation, with no discrete cell cycle stage
arrest relative to that under control miRNA conditions (Fig. 3C
and D). Flow cytometry analyses indicated little sub-G0 DNA con-
tent, consistent with little or no induced apoptosis. The findings
show that the decreased cell proliferation observed with miR-9-3p
in combination with a low dose of MEK inhibitor does not cause
cell cycle stage arrest or progression to apoptosis but, rather,
causes a prolonged progression of the cell cycle.
Specific to MDA-MB-231 cells, cells dually treated with miR-
9-3p and AZD6244 were smaller in size and displayed a dynamic
membrane blebbing (Fig. 3E; see Movie S1 in the supplemental
material). Because of this morphological phenotype, we assessed
the proapoptotic marker BIM in MDA-MB-231 cells. We ob-
served increased BIM levels in MDA-MB-231 cells treated with
miR-9-3p and AZD6244 (Fig. 3F). SUM159PT cells did not
show a membrane blebbing-like morphology, nor did they
show evidence of apoptosis by flow cytometry (Fig. 3C), but
they did show increased BIM protein at 2, 4, and 6 days of
treatment with miR-9-3p plus AZD6244 (Fig. 3G). Despite the
expression of BIM, neither the MDA-MB-231 nor SUM159PT
cells underwent apoptosis. These results suggest that the mem-
brane blebbing-like response is unrelated to apoptosis but that
the increased BIM expression would presumably prime the
cells for apoptosis.
Treatment with miR-9-3p plus MEK inhibitor inhibits cell
migration and invasion. To gain a more detailed understanding
of the miR-9-3p growth suppression phenotype, we performed
multiday time-lapse imaging in a VivaView CO2 incubator micro-
scope, allowing capture of cell phenotypes over time. MDA-MB-
231 cells (Fig. 4A; see Movie S2 in the supplemental material) and
SUM159PT cells (Fig. 4B; see Movie S3 in the supplemental ma-
terial) showed significant inhibition of proliferation when they
were treated with the combination of miR-9-3p and AZD6244. In
addition, the movies clearly showed a marked decrease in random
cell migration (see Movies S2 and S3 in the supplemental mate-
rial). There was no decrease in random migration in control
AZD6244-treated cells in the absence of miR-9-3p expression or
in the miR-9-3p-transfected cells in the absence of AZD6244. To
quantify the migration defect, we performed Transwell migration
assays (Fig. 4C and D). The migration of miR-9-3p-transfected
and AZD6244-treated MDA-MB-231 cells was reduced to 33.4%
of the mean value of AZD6244-treated cells transfected with con-
trol miRNA, while migration was reduced to 36.1% for
SUM159PT cells. The invasive capacity of AZD6244 in the pres-
ence or absence of miR-9-3p was assessed using the Matrigel ma-
trix transwell assay. As observed in the migration assays, treatment
of cells with miR-9-3p plus AZD6244 resulted in a stronger inhi-
bition of invasion than treatment of cells with single agents alone,
with invasion of MDA-MB-231 cells being reduced to 20.9% and
that of SUM159PT cells being reduced to 32.4% of the mean value
of control miRNA-transfected, AZD6244-treated cells (Fig. 4E
and F). Thus, miR-9-3p expression synergizes with MEK inhibitor
for inhibition of proliferation, migration, and invasion of MDA-
MB-231 and SUM159PT cells.
Identification of ITGB1 as an miR-9-3p target. The Micro-
Cosm miRNA target algorithm (13) predicted the presence of two
independent miR-9-3p binding sites within the 3= UTR of the
ITGB1 transcript. Seven base pairs of identity between the ITGB1
transcript and the miR-9-3p seed sequence exist at both putative
target sites (Fig. 5A). A third 3= UTR site, not detected by Micro-
Cosm, harbored the identical seed sequence identity but lacked
homology to the 3= region of miR-9-3p relative to the other two
predicted sites (Fig. 5A). We blotted for endogenous ITGB1 pro-
tein following miR-9-3p mimic transfection of both MDA-MB-
231 and SUM159PT cells (Fig. 5B). ITGB1 protein was markedly
reduced with transfection of miR-9-3p in both cell lines. Expres-
sion of the opposite-strand miR-9-5p mimic had no effect on
ITGB1 protein expression in MDA-MB-231 cells. In addition to
protein levels, miR-9-3p treatment of SUM159PT cells reduced
ITGB1 transcript levels to 44.8% of the levels detected in cells
treated with control miRNA (Fig. 5C). Because the ITGB1 tran-
script loss assessed by quantitative RT-PCR did not appear to be as
complete as the ITGB1 protein loss upon Western blotting, it is
likely that miR-9-3p elicits translational repression effects, in ad-
dition to effects on mRNA stability.
To further confirm that ITGB1 is a target of miR-9-3p, we used
a luciferase reporter vector harboring the ITGB1 3= UTR se-
quence. Transient miR-9-3p overexpression dampened the mean
luciferase readout to 68.0% (P  0.001) of that for cells transfected
with control miRNA, with no luciferase attenuation detected
upon miR-9-5p transfection (Fig. 5D). Combined mutation of the
three ITGB1 3= UTR sites predicted to bind the miR-9-3p seed
sequence (Fig. 5A) completely rescued the luciferase reporter re-
pression caused by transient miR-9-3p overexpression, validating
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FIG 3 miR-9-3p enhances MEK inhibitor-induced growth suppression. (A) Dose-response analysis for MDA-MB-231 cells or SUM159PT cells using the MEK
inhibitor AZD6244 or GSK1120212 in the presence of control, miR-9-3p, or miR-9-5p miRNA mimics, showing growth attenuation with miR-9-3p and growth rescue
with miR-9-5p. Cells were treated with drug and miRNA for 96 h prior to assaying cell viability by CellTiter-Glo luminescence, which was normalized to the value for
control miRNA treated with DMSO. Error bars indicate SEMs of three experiments. (B) Dose-response curves as in panel A normalized to the value for each miRNA
treated with DMSO separately for miR-9-3p or control miRNA. (C) DNA content determined by propidium iodide (PI) flow cytometry of SUM159PT cells 96 h after
miR-9-3p or control miRNA treatment with or without 250 nM AZD6244. High-dose (500 nM) GSK1120212 was used as a positive control for the G0/G1 arrest induced
by MEK inhibition. (D) Cell cycle stage quantification and percent growth inhibition from the flow cytometry data in panel C. (E) DIC image showing enhanced dynamic
blebbing (arrows) after dual treatment of MDA-MB-231 cells with miR-9-3p and 500 nM AZD6244 for 96 h relative to control miRNA treated with DMSO condition.
Bars 
 50 m. See Movie S1 in the supplemental material. (F) MDA-MB-231 cell blotting for endogenous BIM protein 96 h after transfection with the indicated miRNA
mimics and treatment with 1.5 M AZD6244 or DMSO. (G) BIM immunoblotting at 2, 4, and 6 days after transfection of SUM159PT cells with the indicated miRNA
mimics and treatment with 500 nM AZD6244 or DMSO. Loading controls were actin or ERK2.
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that these predicted sites are functional sites of miR-9-3p binding
(Fig. 5E). Together, these data validate, for the first time, ITGB1 as
a target for miR-9-3p.
ITGB1 expression is elevated in claudin-low breast cancer.
We queried the UNC337 gene array database with expression data
comprising tumors of normal-like, luminal A, luminal B, HER2-
enriched, basal-like, and claudin-low intrinsic subtypes for ex-
pression of ITGB1 (6). ITGB1 was more highly expressed in clau-
din-low tumors than the other intrinsic breast cancer subtypes
(Fig. 6; P 
 2.2E5), suggesting a contributing function in the
mesenchymal-like features of claudin-low tumor cells. We
therefore targeted ITGB1 in claudin-low MDA-MB-231 and
SUM159PT cells as a druggable protein regulated by miR-9-3p.
ITGB1 regulation of MDA-MB-231 and SUM159PT cell pro-
liferation, migration, and invasion. We used both siRNA knock-
down of ITGB1 expression and a function-blocking monoclonal
antibody, AIIB2 (29), in experiments to test the function of ITGB1
in MDA-MB-231 and SUM159PT cells (Fig. 7A and B). siRNA
knockdown of ITGB1 expression in both cell types significantly
inhibited proliferation (Fig. 7A), indicating that ITGB1 positively
regulates cell growth. RNAi knockdown of ITGB1 in combination
with AZD6244 further inhibited growth of both cell lines, consis-
tent with ITGB1 being a major target of miR-9-3p whose repres-
sion enhances growth inhibition of the two cell lines by MEK
inhibitor.
At a dose of 2.5 g/ml, the AIIB2 1 integrin function-blocking
antibody significantly enhanced AZD6244 (125 nM)-mediated
growth arrest of SUM159PT cells (with the mean cell counts de-
creasing from 27.6% to 13.9% of the mean cell counts of control
IgG-treated cells in the absence of AZD6244) (Fig. 7B, left). A
4-fold increase in AIIB2 dose synergized with MEK inhibition to
decrease cell viability (to 63.3% of that for control IgG-treated
cells in the absence of AZD6244), despite a lower dose (40 nM
versus 125 nM) of AZD6244 (Fig. 7B, right), demonstrating a
reciprocal dosing relationship between MEK and ITGB1 inhibi-
tion.
As performed for miR-9-3p, we characterized the effect of
siRNA knockdown of ITGB1 on cell cycle progression by pro-
pidium iodide flow cytometry. The effect of ITGB1 siRNA was
concordant with transient transfection of the miR-9-3p mimic,
resulting in overall diminution of cell cycle progression with no
stage-specific arrest (Fig. 7C and D).
Although the AIIB2 antibody had a modest effect on
SUM159PT proliferation relative to siRNA knockdown of ITGB1
(Fig. 7A and B), in the presence of AZD6244, it had robust effects
on both migration and invasion (Fig. 8A to F; see Movies S4 and S5
in the supplemental material). Attenuation of both migration and
invasion by AIIB2 in the presence of MEK inhibitor compared to
that achieved with either agent alone was quantified using Trans-
well assays (Fig. 8A to D). The inhibition of migration and inva-
FIG 4 Inhibition of cell migration and invasion by miR-9-3p plus MEK inhibitor. (A and B) DIC imaging of MDA-MB-231 (A) or SUM159PT (B) cells treated
with miR-9-3p or control miRNA mimic, with or without AZD6244 treatment (MDA-MB-231 cells were treated with 500 nM, SUM159PT cells were treated with
250 nM). Shown is frame 207 of 34- or 42-h time-lapse imaging with 10-min intervals using a 	20 objective, showing reduced proliferation and migration of cells
dually treated with miR-9-3p and AZD6244 (see Movies S2 and S3 in the supplemental material). Bars 
 100 m. (C to F) Transwell migration (C and D) or
Matrigel invasion (E and F) assays for MDA-MB-231 and SUM159PT cells treated with or without miR-9-3p and with or without MEK inhibitor. Cells were
allowed to migrate/invade Transwells for a 24-h duration 48 h after miRNA transfection and pretreatment with 500 nM (MDA-MB-231 cells) or 250 nM
(SUM159PT cells) AZD6244. Error bars indicate SEMs of three experiments. *, P  0.05, **, P  0.01.
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sion seen with the AIIB2 antibody was phenocopied by siRNA
knockdown of ITGB1 (Fig. 8A to D, G, and H; see Movies S6 and
S7 in the supplemental material). Importantly, cell numbers were
normalized before assay of migration and invasion, so that
changes in cell number resulting from growth inhibition did not
significantly contribute to differences in cell number during
Transwell assays. Cumulatively, these results show that inhibition
of ITGB1 function in combination with MEK inhibition has pro-
nounced inhibitory effects on migration and invasion of MDA-
MB-231 and SUM159PT cells.
DISCUSSION
Our synthetic enhancer screen, by design, yielded candidate
growth-suppressive miRNAs. In this study, we verified that miR-
9-3p plays a tumor-suppressive role in the claudin-low cell lines
MDA-MB-231 and SUM159PT. mir-9 is epigenetically silenced by
promoter methylation in these cells, which is a common observa-
tion for many tumor-suppressive miRNAs (30). To date, much of
the miR-9-5p/3p characterization has stemmed from studies in
neurons, where expression is abundant and due to the conserva-
tion of miR-9-5p/3p neural expression across species (31). Studies
exploiting mir-9-2 mir-9-3 double-knockout mice (32) and other
animal models (33, 34) have demonstrated a role for miR-9-5p/3p
in the proliferation and migration of neural progenitor cells. This
has been thought to be in large part due to the direct targeting of
transcription factors by miR-9-5p/3p (35, 36). Furthermore, miR-
9-5p/3p along with miR-124 has been shown to influence neural
fate determination via chromatin remodeling complexes (37).
In addition to these neuronal miR-9-5p/3p functions, increas-
ing attention to its role in cancer has stemmed from initial studies
showing effects on metastasis by miR-9-5p targeting E-cadherin
(18) and multiple studies showing tumor-specific epigenetic si-
lencing of the mir-9 loci in diverse cancer types (9, 22–26). It is
now appreciated that in cancer miRNA functionality is contex-
tual; that is, a given miRNA can be tumor suppressive or onco-
genic, depending on the cell type or environment. This can be due
to the relative abundance of a target mRNA, alternative polyade-
nylation sites resulting in the loss or gain of miRNA transcript
binding sites, or mutation of miRNA binding sites (reviewed in
reference 38). In fact, rather than being epigenetically silenced,
mir-9 was shown to be overexpressed in Hodgkin’s lymphoma
(39), in lymphoma of the central nervous system (40), and in
gastric cancer (41). In our screen, the miR-9-5p strand yielded a
FIG 5 The 1 integrin gene (ITGB1) is a target of miR-9-3p. (A) Alignment of miR-9-3p with two putative binding sites (sites 1 and 2) within ITGB1 3= UTR,
as predicted by MicroCosm Targets v5 (EMBL-EBI). A third site with the identical seed sequence homology but weaker overall homology to miR-9-3p is shown
as site 3. Seed sequence identity is highlighted in red. (B) (Left) Western blot showing the loss of endogenous ITGB1 protein in MDA-MB-231 cells 96 h
posttransfection with the miR-9-3p mimic but not the miR-9-5p mimic in the presence or absence of 500 nM AZD6244; (right) loss of endogenous ITGB1
protein in SUM159PT cells 48 h after transfection with the miR-9-3p mimic in the presence or absence of 250 nM AZD6244. (C) Real-time PCR showing
decreased levels of the ITGB1 transcript in SUM159PT cells 48 h after miR-9-3p mimic transfection. STK25 transcript levels are shown as a negative control. (D)
Dual-luciferase reporter assay showing miR-9-3p dampening of the firefly luciferase transcript linked to the full-length human ITGB1 3= UTR. The firefly
luciferase signal was normalized to the signal obtained for Renilla luciferase to control for transfection efficiency, and this ratio was then normalized to the value
for control miRNA-treated cells for control or ITGB1 3= UTR vectors. Error bars indicate SEMs of 10 replicate wells within a 96-well assay plate. ***, P  0.001.
(E) Loss of miR-9-3p-mediated suppression of luciferase-ITGB1 3= UTR reporter expression with mutation of three predicted miR-9-3p binding sites (A). *, P 
0.05, **, P  0.01. The ITGB1 3= UTR nucleotide substitutions designed to disrupt miR-9-3p seed sequence binding are indicated in red.
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growth phenotype opposite that yielded by our synthetic enhancer
hit, miR-9-3p. In cases where both strands are functional and not
degraded, there are examples of the 5p and 3p strands cooperating
temporally, despite targeting different mRNAs, resulting in a syn-
ergistic effect. An example includes miR-155-5p and miR-155-3p,
whereby the two strands cooperatively regulate the balance of in-
terferon production: miR-155-5p targets IRAKM, resulting in
positive regulation of interferon, while miR-155-3p targets TAB2,
functioning as a negative regulator of the response (42). Interest-
ingly, miR-9-5p and miR-9-3p have been shown to regulate dif-
ferent members of the same transcriptional regulatory complex,
REST/CoREST, which represses transcription of neuronal genes
(36). In our system, the different functional strands have opposing
effects on cell proliferation. This suggests that the miR-9-5p/miR-
9-3p ratios are under strict posttranscriptional regulation in cells
where the mir-9 genes are not silenced.
The identification of miR-9-3p from our primary screen al-
lowed us to subsequently identify a new target for this miRNA,
ITGB1. Humanized function-blocking antibodies (43, 44) against
epithelial 51 heterodimers are now in preclinical, phase I, and
phase II trials. In addition, the small fibronectin peptide antago-
nist of 51 ATN-161 (45–47) entered phase I studies for glioma
and renal cell carcinoma, while the 51 antagonist JSM6427 (48,
49) entered phase I studies for age-related macular degeneration.
FIG 6 Elevated ITGB1 expression in human claudin-low tumors relative to
tumors of the remaining indicated subtypes from the UNC337 gene array
database. P 
 2.2E5 by the unequal variance t test; n 
 337 tumors; whis-
kers 
 1.5 interquartile range.
FIG 7 ITGB1 perturbation potentiates growth inhibition by MEK inhibitor. (A) The effect of 1 integrin perturbation/MEK inhibition on cell proliferation using
ITGB1 siRNA. MDA-MB-231 or SUM159PT cells were treated with 500 nM (MDA-MB-231) or 125 nM (SUM159PT) AZD6244 or DMSO for 96 h, followed by
hemocytometer cell counts. (B) Effect of 1 integrin perturbation/MEK inhibition on SUM159PT cell growth using 2.5 g/ml (left) or 10 g/ml (right) 1
integrin blocking antibody in the presence of 125 nM (left) or 40 nM (right) AZD6244. Growth inhibition was assayed by hemocytometer cell counts or
CellTiter-Glo luminescence 72 h after addition of drug-antibody. Error bars represent SEMs of 3 replicates for panels A and B. *, P  0.05, **, P  0.01, ***, P 
0.001. (C) DNA content determined by propidium iodide flow cytometry of SUM159PT cells 96 h after ITGB1 siRNA or control siRNA treatment with or without
250 nM AZD6244. (D) Cell cycle stage quantification and percent growth inhibition from flow cytometry data in panel C.
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In HER-2-overexpressing breast cancer cells, the ITGB1-inhibi-
tory antibody AIIB2 synergizes with the HER-2 monoclonal anti-
body trastuzumab to increase growth suppression (50). Our data
suggest that such a combinatorial strategy with dual MEK and
ITGB1 inhibition can be effective for two different claudin-low
breast cancer cell lines. The influence of MEK/ERK on integrin
signaling is well established: integrin activation by extracellular
matrix ligation commonly leads to mitogen-activated protein ki-
nase activation via FAK and SRC, while ERK activation can also
influence surface integrin expression (51). The miR-9-3p/MEK
FIG 8 1 integrin perturbation further attenuates cell migration and invasion in the presence of MEK inhibition. (A to D) Transwell migration and Matrigel
invasion assays for MDA-MB-231 (A and B) and SUM159PT (C and D) cells with or without 2.5 g/ml AIIB2 1 integrin inhibitory antibody (top) or with or
without ITGB1 siRNA (bottom) and with or without MEK inhibition. Cells were allowed to migrate/invade for a 24-h duration 48 h after pretreatment with
AZD6244 and AIIB2 antibody or ITGB1 siRNA. Error bars indicate SEMs of three experiments. *, P  0.05; **, P  0.01; ***, P  0.001. (E to H) DIC imaging
of MDA-MB-231 or SUM159PT cells treated with AIIB2 1 integrin blocking antibody (E and F) or ITGB1 siRNA (G, H) with or without AZD6244 treatment.
Shown is frame 122 of 59 h of time-lapse imaging with 20-min intervals using a 	20 objective, showing reduced proliferation and migration of cells treated with
both integrin perturbation and AZD6244 (see Movies S4 to S7 in the supplemental material). Cells dually treated with ITGB1 siRNA and AZD6244 were larger
and displayed a more spread morphology. Bars 
 200 m. AZD6244 was used at 500 nM and 250 nM for MDA-MB-231 and SUM159PT cells, respectively, for
all experiments whose results are presented in Fig. 8.
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inhibition-induced phenotype of decreased proliferation, migra-
tion, and invasion in the absence of apoptosis is consistent with
the purported role of ITGB1 in breast cancer tumor cell dor-
mancy, growth, and metastasis (52, 53). Our analysis of expression
data from the UNC337 database showed that ITGB1 mRNA was
expressed at the highest levels in human claudin-low breast tu-
mors relative to other breast cancer subtypes (6). Data from both
cell lines and TCGA patient breast tumors showed significant cy-
tosine methylation of mir-9 promoter regions, which would be
consistent with the UNC337 breast cancer patient database show-
ing significant ITGB1 mRNA expression in claudin-low tumors.
Claudins have been shown to mediate breast cancer cell metastasis
to liver in part via regulation of surface expression of 21 and
51 integrin heterodimers (54). Thus, elevated integrin expres-
sion in claudin-low tumors might allow a compensation mecha-
nism for low baseline claudin expression in this breast cancer sub-
type.
The claudin-low cell lines employed in this study harbor acti-
vating Ras mutations: G13D KRAS in MDA-MB-231 cells and
G12D HRAS in SUM159PT cells (55). Current evidence suggests
that there is an overall low frequency of Ras mutations in breast
cancer, especially among the HER2-positive and luminal sub-
types. There was a paucity of Ras mutations identified in TCGA
patient breast tumors, with only one activating Ras mutation, of
the basal-like subtype, being found (28). It should be noted that
claudin-low tumors were markedly underrepresented in TCGA
patient tumors, with only 4 or 5 tumors that profiled as claudin
low being found in the entire study (n 
 501). Despite this low
prevalence of activating mutations, 30% of basal-like tumors an-
alyzed in the TCGA study harbored genomic amplification of
KRAS (28). Ras is amplified during tumor progression in the
C3(1)/simian virus 40 TAg mouse model of basal-like/claudin-
low breast cancer, whereby comparative genomic hybridization
analysis revealed up to 40-fold amplification of the KRAS locus
(56). In addition to many claudin-low human cell lines having
activating Ras mutations, each of the murine cell lines established
from the C3 TAg GEMM and the T11 claudin-low mouse model
(57) has activating Ras mutations. Thus, the role of activating Ras
mutations in claudin-low breast cancer is just beginning to be
defined. A role for mutant Ras in different tumor types where Ras
has not previously been thought to play a role is illustrated in a
recent study that documented a selection for a mutant Ras leuke-
mia in melanoma patients receiving the Raf inhibitor vemurafenib
(58). An analogous enrichment for mutant or amplified Ras may
be occurring in claudin-low tumors. Thus, we believe that the
relevance of the findings presented here are truly representative of
the claudin-low subtype.
The findings support a model whereby in claudin-low breast
cancer cells there is sufficient methylation at the promoters of each
of the mir-9 genomic loci to significantly silence expression that
could result in diminished miR-9-3p-mediated regulation of
ITGB1 expression. This could increase integrin and c-MYC ex-
pression, whereby the cells could have enhanced migration and
invasion as well as the potential for increased proliferation. Low-
dose AZD6244 or GSK1120212 synergized with miR-9-3p to elicit
the inhibition of growth, migration, and invasion. A key aspect of
AZD6244 inhibition of MEK-ERK activity in claudin-low cell
lines is enhanced c-MYC degradation, with subsequent kinome
reprogramming leading to RTK upregulation (10), and loss of the
c-MYC protein strongly suppresses growth of claudin-low breast
cancer cells (59). miR-9-3p sustained the loss of c-MYC expres-
sion in the presence of MEK inhibitor. miR-9-3p also inhibited
ITGB1 expression, and the loss of ITGB1 inhibited MDA-MB-231
and SUM159PT cell growth. Thus, the combination of MEK in-
hibitor and mIR-9-3p has a cumulative effect of inhibiting both
ITGB1 and c-MYC functions.
In cells where mir-9 loci are not silenced, ITGB1 signaling may
be attenuated by miR-9-3p, yielding a baseline level of integrin
function, as opposed to a more aggressive invasive/migratory phe-
notype. Consistent with this notion, miR-9-3p expression has
been shown to be significantly lower in metastatic tumors than
primary tumors (60). In sum, the results show that miR-9-3p
silencing can be pharmacologically overcome using MEK inhibi-
tor in combination with ITGB1 inhibition in claudin-low cells;
similar approaches using synthetic enhancement screens should
identify additional druggable targets of silenced tumor-suppres-
sive miRNAs.
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